SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
Clinical trial NCT06889493 · RECRUITING
Trial details
- NCT number
- NCT06889493
- Sponsor
- Peter Hosein, MD
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-19
- Primary completion
- 2030-06-01
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.